Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Magnetar Financial LLC’s 7th Largest Position

Magnetar Financial LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1,445.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 108,150 shares of the biopharmaceutical company’s stock after buying an additional 101,150 shares during the period. Regeneron Pharmaceuticals comprises about 1.8% of Magnetar Financial LLC’s holdings, making the stock its 7th biggest position. Magnetar Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $77,038,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Teacher Retirement System of Texas boosted its holdings in shares of Regeneron Pharmaceuticals by 32.5% in the 4th quarter. Teacher Retirement System of Texas now owns 38,932 shares of the biopharmaceutical company’s stock worth $27,732,000 after purchasing an additional 9,554 shares during the period. Royal London Asset Management Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 0.9% in the 4th quarter. Royal London Asset Management Ltd. now owns 44,084 shares of the biopharmaceutical company’s stock worth $31,402,000 after purchasing an additional 409 shares during the period. Kazazian Asset Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $399,000. Harvest Fund Management Co. Ltd lifted its stake in shares of Regeneron Pharmaceuticals by 27.4% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 6,360 shares of the biopharmaceutical company’s stock worth $4,388,000 after acquiring an additional 1,366 shares during the last quarter. Finally, Vinva Investment Management Ltd lifted its stake in shares of Regeneron Pharmaceuticals by 45.5% during the 4th quarter. Vinva Investment Management Ltd now owns 3,779 shares of the biopharmaceutical company’s stock worth $2,655,000 after acquiring an additional 1,182 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.1 %

Shares of REGN stock opened at $672.36 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The stock’s fifty day moving average price is $691.62 and its 200 day moving average price is $822.93. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market cap of $73.51 billion, a price-to-earnings ratio of 17.56, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the business earned $11.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. TD Cowen decreased their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Finally, Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.